Pericardium Diseases Market Research Report- Forecast till 2027

Pericardium Diseases Market Research Report: By Types (Acute Pericarditis, Hemopericardium, Pericarditis, Tuberculosis Pericarditis), Treatment (Diagnostic Test, Disease Treatment), End Users (Hospital & Clinics, Ambulatory Centers) - Forecast till 2027

ID: MRFR/Pharma/3467-HCR | | Region: Global | 85 pages

Pericardium Diseases Market Scenario:


The pericardium is a double-layered, tough, collagenous membrane, which surrounds the heart. They play an important role in the protection of the health from external shock. Nowadays, a number of companies manufacture artificial tissue membrane, which is widely used in the surgical procedures of pelvic floor reconstruction and bariatric stomach reduction. Many factors are responsible for the diseases, which includes infections, heart surgery, trauma, cancer and many other diseases. Pericarditis is the most common type of the disease. It affects people of all ages, however, men between 20 years-50 years are more likely to develop the disease. In 15%-30% cases, it develops into chronic pericarditis. Increasing prevalence of pericarditis across the globe is a major driver of the market. According to the Health Grades Inc, 1 in every 2,000 individual have pericarditis. Additionally, high healthcare expenditure, increasing demand for the better treatment, and rising number of patients with heart diseases are providing support for the growth of the market. However, available treatments are costly and are not affordable to peoples in developing countries. Thus, the high cost of the treatment may slow the growth of the market.


The pericardium diseases market is expected to grow at a CAGR of ~8.2 % during the forecast period 2017-2023. 


Figure 1- Market Synopsis of the Global Pericardium Diseases Market Research, by Region, 2016 (%) Pericardium Diseases Market


Sources- WHO, cancer research UK, American Cancer Society, press release, annual report


Segmentation 


The global pericardium diseases market is segmented on the basis of types, treatment, and end users.


On the basis of the types, the market is segmented into acute pericarditis, hemopericardium, pericarditis, tuberculous pericarditis, and others.


On the basis of the treatment, the market is segmented into diagnostic test, and disease treatment. The diagnostic treatment is further segmented into the physical exam, EKG, chest X-ray, echocardiography, cardiac CT, cardiac MRI, and others. The diseases treatment is sub-segmented into anti-inflammatory drugs, pericardium patches, surgery, and others.


On the basis of the end users, the market is segmented into hospital & clinics, ambulatory centers, and others. 


Regional Analysis 


The Americas account for the major share of the global pericardium diseases market owing to the increasing number of patients with pericardium diseases, well-developed technology, and increasing government support for research & development. Additionally, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas pericardium diseases market. Presence of major players in this region is likely to support the growth of the market during the forecasted period. Europe holds the second largest pericardium diseases market, which is followed by Asia Pacific. Strong government support and availability of the funds for research & development have driven the market growth. Germany and the U.K are the major contributors to the market. Asia Pacific is the fastest growing pericardium diseases market owing to the presence rapidly developing the economy, increasing the prevalence of cancer and other heart diseases, and increasing government support. On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa, and limited availability of funds and medical facilities. The Middle East dominates the Middle East & Africa pericardium disease market due to the presence of well-developed countries like Kuwait, Qatar, Oman, and South Arabia. However, due to the presence of a huge opportunity for the development of the market, Africa region is expecting a healthy growth.


Market Assessment Global Pericardium Diseases Market


Sources- WHO, cancer research UK, American Cancer Society, press release, annual report


 Key Players in Global Pericardium Market


Some of key the players in the pericardium diseases market are Smith and Nephew (U.K), Teva Pharmaceutical (Isreal), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Arthrex, Inc.(U.S.), Medtronic (U.K), Edwards Lifesciences (U.S.), Abbott Laboratories (U.S.), Johnson & Johnson Services, Inc. (U.S.), C.R. Bard Inc (U.S.)Allergan (U.S.), Integra Lifesciences (U.S.), Livanova(U.K), and Zimmer Biomet (U.S.)


Intended Audience



  • Pharmaceutical Companies

  • Government and private research companies

  • Research and Development (R&D) Companies

  • Drug Manufacturers and Suppliers

  • Medical Research Laboratories 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2018-2023: 6.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, treatment, and end users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Increasing prevalence of pericarditis across the globe
  Key Market Opportunities

  • High healthcare expenditure
  • Increasing demand for the better treatment
  •   Key Market Drivers   Increasing prevalence of pericarditis across the globe


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The pericardium diseases market CAGR during the forecast period would be 8.2%.

    The largest pericardium diseases market is the Americas.

    The fastest-growing pericardium diseases market would be Asia Pacific.

    End users included in the pericardium diseases market report are ambulatory centers, hospital & clinics, and others.

    The pericardium diseases market players are Teva Pharmaceutical (Israel), Smith and Nephew (U.K), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K), Arthrex, Inc.(U.S.), Eli Lilly and Company (U.S.), Edwards Lifesciences (U.S.), Medtronic (U.K), Johnson & Johnson Services, Inc. (U.S.), Abbott Laboratories (U.S.), Allergan (U.S.), C.R. Bard Inc (U.S.), Livanova (U.K), Integra Lifesciences (U.S.), and Zimmer Biomet (U.S.).

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Pericardium Diseases Market, by Types

    6.1 Introduction

    6.2 Acute Pericarditis

    Market Estimates & Forecast, 2020 – 2027

    6.3 Hemopericardium

    Market Estimates & Forecast, 2020 – 2027

    6.4 Pericarditis

    Market Estimates & Forecast, 2020 – 2027

    6.5 Tuberculous Pericarditis

    Market Estimates & Forecast, 2020 – 2027

    6.6 Others

    Chapter 7. Global Pericardium Diseases Market, by Treatment

    7.1 Introduction

    7.2 Diagnostic Test

    Market Estimates & Forecast, 2020 – 2027

    7.2.1 Physical Exam

    7.2.1.1 EKG

    7.2.1.2 Chest X Ray

    7.2.1.3 Echocardiography

    7.2.1.4 Cardiac CT

    7.2.1.5 Cardiac MRI

    7.2.1.6 Others

    7.3 Disease Treatment

    Market Estimates & Forecast, 2020 – 2027

    7.4.1 Anti-Inflammatory Drugs

    7.4.2 Pericardium Patches

    7.4.3 Surgery

    7.4.4 Others

    Chapter 8 Global Pericardium Diseases Market, by End User

    8.1 Introduction

    8.2 Hospital & Clinics

    Market Estimates & Forecast, 2020 – 2027

    8.3 Ambulatory Centers

    Market Estimates & Forecast, 2020 – 2027

    8.4 Others

    Chapter 9. Global Pericardium Diseases Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.1 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Smith and Nephew

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 GlaxoSmithKline Plc.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Bayer AG

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Novartis AG

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Teva Pharmaceutical

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Arthrex, Inc.

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.7 Eli Lilly and Company

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financial

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Others

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Pharmaceutical industry

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Pericardium Diseases Industry Synopsis, 2020 – 2027

    Table 2 Global Pericardium Diseases Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Global Pericardium Diseases Market by Region, 2020 – 2027, (USD Million)

    Table 4 Global Pericardium Diseases Market by Types, 2020 – 2027, (USD Million)

    Table 5 Global Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 6 Global Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 7 North America Pericardium Diseases Market by Types, 2020 – 2027, (USD Million)

    Table 8 North America Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 9 North America Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 10 US Market by Types, 2020 – 2027, (USD Million)

    Table 11 US Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 12 US Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 13 Canada Market by Types, 2020 – 2027, (USD Million)

    Table 14 Canada Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 15 Canada Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 16 South America Market by Types, 2020 – 2027, (USD Million)

    Table 17 South America Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 18 South America Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 19 Europe Market by Types, 2020 – 2027, (USD Million)

    Table 20 Europe Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 21 Europe Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 22 Western Europe Market by Types, 2020 – 2027, (USD Million)

    Table 23 Western Europe Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 24 Western Europe Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 25 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

    Table 26 Eastern Europe Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 27 Eastern Europe Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 28 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

    Table 29 Asia Pacific Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 30 Asia Pacific Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    Table 31 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

    Table 32 Middle East & Africa Pericardium Diseases Market by Treatment, 2020 – 2027, (USD Million)

    Table 33 Middle East & Africa Pericardium Diseases Market by End Users, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Pericardium Diseases Market

    Figure 3 Segmentation Market Dynamics for Global Pericardium Diseases Market

    Figure 4 Global Pericardium Diseases market Share, by Type 2020

    Figure 5 Global Pericardium Diseases market Share, by Treatment 2020

    Figure 6 Global Pericardium Diseases Market Share, by End Users, 2020

    Figure 7 Global Pericardium Diseases Market Share, by Region, 2020

    Figure 8 North America Pericardium Diseases Market Share, by Country, 2020

    Figure 9 Europe Pericardium Diseases Market Share, by Country, 2020

    Figure 10 Asia Pacific Pericardium Diseases Market Share, by Country, 2020

    Figure 11 Middle East & Africa Pericardium Diseases Market Share, by Country, 2020

    Figure 12 Global Pericardium Diseases Market: Company Share Analysis, 2020 (%)

    Figure 13 Smith and Nephew: Key Financials

    Figure 14 Smith and Nephew: Segmental Revenue

    Figure 15 Smith and Nephew: Geographical Revenue

    Figure 16 GlaxoSmithKline Plc..: Key Financials

    Figure 17 GlaxoSmithKline Plc..: Segmental Revenue

    Figure 18 GlaxoSmithKline Plc..: Geographical Revenue

    Figure 19 Bayer AG: Key Financials

    Figure 20 Bayer AG: Segmental Revenue

    Figure 21 Bayer AG: Geographical Revenue

    Figure 22 Novartis AG: Key Financials

    Figure 23 Novartis AG: Segmental Revenue

    Figure 24 Novartis AG: Geographical Revenue

    Figure 25 Teva Pharmaceutical: Key Financials

    Figure 26 Teva Pharmaceutical: Segmental Revenue

    Figure 27 Teva Pharmaceutical: Geographical Revenue

    Figure 28 Arthrex, Inc.: Key Financials

    Figure 29 Arthrex, Inc.: Segmental Revenue

    Figure 30 Arthrex, Inc.: Geographical Revenue

    Figure 31 Eli Lilly and Company: Key Financials

    Figure 32 Eli Lilly and Company: Segmental Revenue

    Figure 33 Eli Lilly and Company: Geographical Revenue